Private Advisor Group LLC Buys 16,219 Shares of Roivant Sciences Ltd. $ROIV

Private Advisor Group LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 135.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,164 shares of the company’s stock after buying an additional 16,219 shares during the quarter. Private Advisor Group LLC’s holdings in Roivant Sciences were worth $780,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. increased its stake in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in Roivant Sciences during the fourth quarter worth about $47,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC boosted its holdings in shares of Roivant Sciences by 141.6% in the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after purchasing an additional 1,704 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. The trade was a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,345,687 shares of company stock valued at $77,017,443 in the last 90 days. 10.80% of the stock is owned by insiders.

Roivant Sciences Trading Up 1.2%

Shares of NASDAQ:ROIV opened at $34.91 on Wednesday. The stock’s 50-day moving average price is $31.33 and its 200-day moving average price is $27.95. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00. The stock has a market capitalization of $25.11 billion, a P/E ratio of -58.18 and a beta of 1.11.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same quarter in the previous year, the business earned ($0.29) earnings per share. As a group, research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Guggenheim increased their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.